Disc Medicine (IRON) Insider Liam Ratcliffe Buys 6,212 Shares

Insider Buying and Selling at Disc Medicine, Inc.

On June 18, 2026, Disc Medicine, Inc. insider Liam Ratcliffe picked up 6,212 shares of the company stock, ticker IRON on the NasdaqGM. This transaction arrived during a flurry of insider moves at the clinical-stage biopharmaceutical firm throughout the month of June, highlighting active internal participation in the equity.

Recent Insider Transactions at Disc Medicine

The executive team and other insiders have been notably active in recent weeks. On June 28, Chief Legal Officer Rahul Khara purchased 851 shares at $14.69 apiece for a total value of $12501.19, following an earlier acquisition of 7,500 shares on June 18 at the same price of $14.69, totaling $110175.0. Chief Operating Officer Yu Jonathan Yen-Wen also engaged with the stock, first buying 18,612 shares at $9.86 on June 16 for a value of $183514.32 before later parting with 9,700 shares on June 22. Additionally, Nadim Ahmed acquired 5,176 shares on June 18.

Disc Medicine Stock Performance and Valuation

Shares of Disc Medicine traded around $70.80, positioning the equity well above its 52-week low of $40.00 and below its peak of $99.50. The company carries a market cap of roughly $2.63 billion alongside a 50-day moving average of $76.60 and a 200-day moving average of $73.03. With an earnings per share figure of -$6.59, the firm currently has no meaningful P/E ratio because it is not profitable.

Wall Street Analyst Ratings and Price Targets

Analyst coverage remains optimistic as multiple firms updated their views on Disc Medicine over the summer. On August 6, HC Wainwright & Co. maintained its buy rating while adjusting its price target to $120.00 from $118.00. Wedbush followed by reiterating its outperform rating with a $100.00 target on September 2, and again on September 10. Later, on September 16, Wells Fargo kept an overweight rating while lifting its target to $86.00 from $79.00. Across the broader analyst community, the stock holds a strong buy consensus with a mean price target of $103.17 based on twelve opinions.

What Disc Medicine Does

Disc Medicine is a Watertown, Massachusetts-based biotech firm with 165 employees focused on discovering and developing treatments for serious hematologic diseases. Its pipeline works on pathways connected to red blood cell formation and iron homeostasis, targeting conditions like erythropoietic porphyrias and myelofibrosis.

Looking Ahead at Financial Milestones

Investors can track further developments when the company delivers its next scheduled financial report on November 5, 2026. These updates will offer additional context on clinical trial progress for its various product candidates.